Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.
Johnna E PerdrizetEmily K HornWinniefer NuaJudith Perez-PeraltaJennifer M NailesJaime SantosAnna Ong-LimPublished in: Infectious diseases and therapy (2021)
PCV13-PFE would prevent exceedingly more cases and deaths compared with lower-valent PCVs. Additionally, the PCV13-PFE program is estimated to continue providing cost-savings, offering the best value for money to achieve universal PCV coverage in the Philippines.